Table 2.
Patients, n (%) | Mean ± SD
|
||||
---|---|---|---|---|---|
|
Screening
|
Change from screening at baseline
|
|||
n=125 | 9 am | 11 am | 9 am | 11 am | |
Monotherapy | |||||
PG | 42 (34) | 16.8±2.8 | 16.9±2.4 | 2.9±2.0 | 3.0±2.0 |
β-blocker | 22 (18) | 19.0±3.4 | 19.2±3.5 | 1.9±1.9 | 1.4±2.5 |
Concomitant therapy with two drugsa | |||||
PG/β-blocker | 34 (27) | 17.4±3.5 | 17.4±3.6 | 3.5±2.3 | 4.0±3.0 |
PG/CAI | 5 (4) | 16.2±1.5 | 16.2±2.2 | 5.2±1.9 | 6.0±0.7 |
β-blocker/CAI | 10 (8) | 16.3±3.5 | 16.5±3.5 | 3.1±3.5 | 3.4±2.2 |
Concomitant therapy with three drugsa | |||||
PG/β-blocker/CAI | 8 (6) | 17.6± 1.1 | 18.3± 1.4 | 6.5±2.6 | 6.6±3.7 |
Other | 4 (3) | 16.5±2.6 | 17.0±2.6 | 1.8±2.2 | 1.0±0.8 |
Note:
Fixed or unfixed combinations.
Abbreviations: CAI, carbonic anhydrase inhibitor; PG, prostaglandin analog; SD, standard deviation.